Earnings call transcript: Haivision Q3 2026 revenue slips as stock falls 7.6%

Haivision reported fiscal Q3 2026 revenue of CAD 34.5 million, down 1.4% year over year and 1.8% below the CAD 35.12 million forecast, while adjusted EBITDA fell 57.1% to CAD 1.5 million and gross margin contracted 260bps to 69.4%. The company posted a CAD 2.1 million net loss versus CAD 0.2 million of net income a year earlier, driven by component costs, extended lead times and tariffs; shares fell 7.57% after hours to $3.91. Haivision maintained CAD 140-142 million full-year revenue guidance but expects to land near the low end, with tariffs affecting roughly 30% of sales and potentially cutting near-term gross margin by about 3 percentage points. Management cited no project cancellations and highlighted growing demand for new products targeting 2027 and beyond, but near-term profitability and procurement timing remain pressured.

Analysis

HAI’s issue is not the modest top-line miss; it is the collapse in incremental profitability at a time when fixed operating costs have stabilized. A further roughly 300bp tariff drag layered on already-compressed gross margin implies Q4 EBITDA can approach breakeven absent an unusually strong revenue conversion. That makes the low end of guidance less important than whether management can prevent a second consecutive quarter of negative operating leverage.

The inventory build is a more consequential risk than the stated cash balance suggests. Inventory and share repurchases have been financed partly through the revolver, so delayed broadcast and government deployments convert what management describes as supply assurance into working-capital absorption and potentially weaker free cash flow. The fulfillment workaround reduces tariff incidence but does not eliminate higher component costs; its success should be judged by Q4 gross margin and inventory turns, not by management’s estimate of mitigation.

Near term, the stock may remain technically weak through the Q4 report as investors de-risk a guidance miss and reset margin assumptions. Over 6-18 months, the new-product cycle could create operating leverage if the company enters adjacent high-bandwidth video workflows and defense modernization budgets recover; however, enthusiasm from product demonstrations is not evidence of orders, and revenue recognition appears too distant to support a rerating today. The contrarian opportunity is eventual value realization from a depressed enterprise value, but only after evidence that gross margin has bottomed and the revolver/inventory cycle is reversing.

CF is not a clean read-through despite tariff exposure in the theme data; HAI’s cost pressure is electronics- and cross-border-fulfillment-specific. The more relevant second-order beneficiaries are larger video infrastructure vendors and diversified defense-electronics suppliers that can source at scale and absorb procurement delays, including LHX and TDY, although neither is a pure public comparable.

Key Decisions for Investors

• Maintain an underweight/short bias in HAI through the Q4 results window (roughly 1-3 months); target downside is a retest below the current range if Q4 gross margin falls toward the implied mid-60% area or EBITDA approaches breakeven. Cover if revenue guidance is achieved without margin deterioration and inventory declines sequentially.
• Do not bottom-fish HAI solely on the post-earnings selloff. Create a long watch trigger only if the next report shows gross margin stabilizing above 68%, inventory falling sequentially, and net revolver usage declining; those metrics would validate that tariff and supply-chain costs are transient rather than structural.
• For defense-video exposure, prefer long LHX or TDY over HAI on a 6-12 month horizon: diversified program exposure and procurement scale should better monetize ISR/readiness spending while avoiding HAI’s customer-concentration and working-capital risk. Reassess if U.S. defense appropriations or continuing-resolution delays materially defer program funding.
• Monitor HAI’s Q4 guide and the conversion of named new-product interest into booked backlog or purchase orders. Absent disclosed order conversion, treat 2027 product-cycle claims as valuation optionality rather than earnings support.